Table 5.
Analysis of drug resistance of E. coli BSI in pancreatic cancer and nonpancreatic patients.
| Antibiotic | Pancreatic cancer (n = 100) | Nonpancreatic cancer (n = 597) | P value |
|---|---|---|---|
| ESBL | 49.0 | 48.1 | 0.898 |
| Ampicillin | 82.0 | 80.6 | 0.799 |
| Piperacillin | 60.0 | 61.6 | 0.817 |
| Ampicillin/sulbactam | 52.0 | 45.1 | 0.329 |
| Piperacillin/tazobactam | 3.0 | 2.7 | 0.766 |
| Cefazolin | 55.0 | 51.4 | 0.61 |
| Cefuroxime | 49.0 | 50.3 | 0.854 |
| Ceftazidime | 23.0 | 20.8 | 0.707 |
| Ceftriaxone | 51.0 | 49.7 | 0.854 |
| Cefepime | 16.0 | 12.7 | 0.506 |
| Cefotetan | 2.0 | 2.2 | 0.693 |
| Aztreonam | 30.0 | 30.2 | 0.975 |
| Imipenem | 0.0 | 0.2 | 0.803 |
| Meropenem | 0.0 | 0.2 | 0.803 |
| Amikacin | 3.0 | 0.8 | 0.268 |
| Gentamicin | 39.0 | 48.7 | 0.167 |
| Tobramycin | 10.0 | 10.7 | 0.871 |
| Ciprofloxacin | 39.0 | 50.9 | 0.091 |
| Levofloxacin | 38.0 | 48.1 | 0.149 |
| Sulfamethoxazole | 57.0 | 60.1 | 0.656 |